Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danilo Perrotti

Showing results (31-40 of 87) with videos related to

Pageof 9
Sort By:
Blood|November 19, 2005
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translationMario Notari, Paolo Neviani, Ramasamy Santhanam, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2008
TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cellsRossana Trotta, Jessica Dal Col, Jianhua Yu, et al.
Molecular Cancer Therapeutics|February 11, 2021
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal DegradationMario Scarpa, Prerna Singh, Christopher M Bailey, et al.
Haematologica|January 19, 2011
The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issuesRichard A Van Etten, Steffen Koschmieder, Francois Delhommeau, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2007
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cellsShujun Liu, Rebecca B Klisovic, Tamara Vukosavljevic, et al.
Blood|October 24, 2002
CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemiaBao-Tran H Truong, Young-Jin Lee, Tracey A Lodie, et al.
Cancer Cell|July 9, 2010
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-AblMark A Gregory, Tzu L Phang, Paolo Neviani, et al.
Blood|June 13, 2009
Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic miceStefan Costinean, Sukhinder K Sandhu, Irene M Pedersen, et al.
Oncotarget|July 21, 2016
Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemiaKamilla M E Laidlaw, Samuel Berhan, Suhu Liu, et al.
Blood|October 11, 2007
Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesisAnna M Eiring, Paolo Neviani, Ramasamy Santhanam, et al.
Pageof 9

Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
Blood|November 19, 2005
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translationMario Notari, Paolo Neviani, Ramasamy Santhanam, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2008
TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cellsRossana Trotta, Jessica Dal Col, Jianhua Yu, et al.
Molecular Cancer Therapeutics|February 11, 2021
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal DegradationMario Scarpa, Prerna Singh, Christopher M Bailey, et al.
Haematologica|January 19, 2011
The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issuesRichard A Van Etten, Steffen Koschmieder, Francois Delhommeau, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2007
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cellsShujun Liu, Rebecca B Klisovic, Tamara Vukosavljevic, et al.
Blood|October 24, 2002
CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemiaBao-Tran H Truong, Young-Jin Lee, Tracey A Lodie, et al.
Cancer Cell|July 9, 2010
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-AblMark A Gregory, Tzu L Phang, Paolo Neviani, et al.
Blood|June 13, 2009
Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic miceStefan Costinean, Sukhinder K Sandhu, Irene M Pedersen, et al.
Oncotarget|July 21, 2016
Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemiaKamilla M E Laidlaw, Samuel Berhan, Suhu Liu, et al.
Blood|October 11, 2007
Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesisAnna M Eiring, Paolo Neviani, Ramasamy Santhanam, et al.
Pageof 9